Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 1.00 |
| ▸ | CKS1B | P61024 | 2/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 2/20 | 1.00 |
| ▸ | SKP1 | P63208 | 1/20 | 1.00 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 12/20 | 0.58 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375858 | 1.00 | HSP90AA1 (1.00) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL14431702 | 0.87 | HSP90AA1 (0.77) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL415185 | 0.85 | CKS1B (1.00) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL16279523 | 0.83 | CKS1B (0.81) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL15536091 | 0.81 | HSP90AA1 (0.68) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL18263261 | 0.81 | CKS1B (0.67) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL182501 | 0.80 | HSP90AA1 (0.67) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL4973506 | 0.80 | HSP90AA1 (0.67) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| Adamantane SCHEMBL27774428 | 0.80 | HSP90AA1 (0.66) | HSP90AA1CKS1BSKP2SKP1HKDC1 | |
| SCHEMBL5794016 | 0.78 | HKDC1 (1.00) | HSP90AA1CKS1BSKP2SKP1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| CN-101896177-A | Combination of therapeutic agents for the treatment of cancer | NOVARTIS AG | 2010-11-24 | — | — | CN | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12616679-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005053704-A1 | METHOD FOR PREDICTING DRUG RESPONSIVENESS IN MYELOID NEOPLASMS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-20050113384-A1 | Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents | AVRAMIS IOANNIS A (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005027972-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| EP-1441717-A1 | COMBINATION OF AN ATP-COMPETITIVE INHIBITOR OF BCR/ABL KINASE ACTIVITY AND A TYRPHOSTIN ANALOG | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037322-A1 | COMBINATION OF AN ATP-COMPETITIVE INHIBITOR OF BCR/ABL KINASE ACTIVITY AND A TYRPHOSTIN ANALOG | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | HSP90AA1 833/4885CKS1B 93/4885SKP2 75/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | HSP90AA1 2926/4885CKS1B 425/4885SKP2 676/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | HSP90AA1 4165/4885CKS1B 1696/4885SKP2 1193/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | HSP90AA1 1326/4885CKS1B 2774/4885SKP2 2385/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | HSP90AA1 3418/4885CKS1B 1690/4885SKP2 1215/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | HSP90AA1 3121/4885CKS1B 424/4885SKP2 267/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | HSP90AA1 2935/4885CKS1B 425/4885SKP2 400/4885 |
| US-12616679-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof | GLUL, QPCT, QPCTL | HSP90AA1 4495/4885CKS1B 1625/4885SKP2 1021/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | HSP90AA1 1649/4885CKS1B 145/4885SKP2 485/4885 |
| US-20050113384-A1 | Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents | AURKC, CLK1, TTK | HSP90AA1 790/4885CKS1B 26/4885SKP2 153/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | HSP90AA1 3904/4885CKS1B 3310/4885SKP2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.